Prof. Univ. Dr. Nikolaos Drakoulis

Member of the Central Committee Drug Approval ((CHMP) and Pharmacogenetics Commission to the European Medicines Agency (EMEA)

Prof. Univ. Dr. Nikolaos Drakoulis

Member of the Central Committee Drug Approval ((CHMP) and Pharmacogenetics Commission to the European Medicines Agency (EMEA)

Curiculum Vitae

Studies

  • 1979 Biochemistry University Tobingen Germany
  • 1986 Medical Degree University Forum. Berlin, Berlin Freie Universirdt
  • 1986 Medical practice license
  • 1989 proclaimed a Doctor of the Berlin University (magna cum laude)
  • 1991 Specialty Clinical and Molecular Genetics at the Human Genetics Institute (Institut für Humangenetik)
  • 1992 Diploma responsible for safety of medical equipment Laser, University of Berlin
  • 1993 Medical Degree Specialization Clinical Pharmacology, Berlin
  • 1994 Medical Degree Specialization Clinical Chemistry, Athens

Fields of Research Activity

  • Pharmacogenetics, Pharmacogenomics, (Proteomics, Metobonomics), pharmacoepidemiology and Molecular Microbiology.
  • Biochemical methods (GC, HPLC) and molecular genetic methods (PCR, RFLP, DNA-arrays, etc.) to identify the phenotype and genotype polymorphisms of metabolic enzymes and their expression in various tissues of the human in order to individualize medication and the intake side effects.
  • Pharmacogenetic approaches in human cancer.
  • He teaches undergraduate courses Pharmacology I and Pharmacology II (5th and 6th semester) and postgraduate studies in “Pharmaceutical-Clinical Pharmacology” and “Industrial Pharmacy» Clinical Pharmacology, Pharmacogenetics and pharmacogenomics.
  • Supervise dissertations specialization “Clinical Pharmacology-Pharmacy ‘and doctoral theses.

distinctions

  • University assistant Institute of Clinical Pharmacology of the University Hospital Klinikum Steglitz, Berlin (1986 – 1989)
  • University assistant of the Institute of Human Genetics (Institut für Humangenetik) in Pediatrics (Kaiserin Augusta Victoria Kinderklinik) University Hospital Rudolf Virchow, Berlin (1989-1991)
  • Lecturer at the University of Berlin Freie Universität Berlin headquarters of Clinical Pharmacology (1991 – 1993)
  • Assistant professor of Clinical Pharmacology at the University of Berlin Humboldt Universität zu Berlin (1993 – 1998)
  • Visiting professor of Clinical Pharmacology at the University of Berlin Humboldt Universität zu Berlin (from 1998).
  • Assistant Clinical Professor of Pharmacy at the Pharmaceutical faculty of the University of Athens (since 2001)
  • Medical director of Clinical Pharmacology Laboratory, Sector High Pressure Liquid Chromatography (HPLC) and Gas Chromatography (GC) in the Institute of Clinical Pharmacology of the University Hospital Klinikum Steglitz, Berlin (1987-1991)
  • Medical officer of Pharmacoepidemiology Pharmacogenetics and laboratory, Institute of Clinical Pharmacology at the University Hospital Klinikum Steglitz, Berlin (1991 – 1993)
  • Medical Officer and responsible for the equipment of Pharmacogenetics Laboratory Polymorphic Metabolic Enzymes sector, the Institute of Clinical Pharmacology of the University Hospital Charit, Berlin (1993)
  • Member of the Central Committee Drug Approval ((CHMP) and Pharmacogenetics Commission to the European Medicines Agency (EMEA), the Greek Society of Pharmacology (NEB), the Greek Society of Clinical Chemistry (EEKCH), European (ESHG) and the German Genetics Society ( GfH), the German Society of Clinical Pharmacology and Therapeutics (DGKPT), the International Society for the Study of xenobiotics (ISSX), the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)

recent Posts

  • J. Brockmφller, R. Kerb, N. Drakoulis, B. Staffeldt, I. Roots: Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: A case-control study. Cancer Research 54, 4103-4111 (1994)
  • N. Drakoulis, I. Cascorbi, J. Brockmφller, C.R. Gross, I. Roots: Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′ flanking region. Clin. Invest., 72, 240-248 (1994)
  • P.M. Mrozikiewicz, N. Drakoulis, I. Roots: Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin. Pharmacol. Ther., 56, 6, 626 (1994)
  • I. Cascorbi, N. Drakoulis, J. Brockmφller, A. Maurer, K. Sperling, I. Roots: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am. J. Hum. Genet. 57, 581-592 (1995)
  • A. Paraskevaidis, N. Drakoulis, I. Roots, C.E. Orfanos, Ch.C. Zouboulis: The role of cytochrome P-450 in Acne. J. Invest. Dermatol. 108, 3, 385 (1997).
  • A. Paraskevaidis, N. Drakoulis, I. Roots, C.E. Orfanos, Ch.C. Zouboulis: Polymorphisms in the human cytochrome P-450 1A1 gene (CYP1A1) as a factor for developing Acne. Dermatology 196, 171-175 (1998).
  • N. Drakoulis. Review: Pharmacogenetics – Pharmacogenomics. The way to individualization of therapy. Pharmakeftiki 17, II, 30-37 (2004)
  • A. McCarthy, M. Kerr, S.-D. Chibout, G. Imbert, N. Cohen, N. Drakoulis, L.E. Knudsen, B. Flamion, L. Hashimoto. Report on the joint EFPIA, DIA and EMEA Pharmacogenetics workshop. Pharmacogenomics 5,731–739 (2004)
  • N. Drakoulis, Ε. Malliara, Κ. Balaskonis, Ε. Haliassos, S. Bauer, C. Skarleas, K. Kyprianou: Genetic Polymorphism and Chemical Carcinogenesis. Assessment of the Enzymes’ NAT2, CYP2A6 AND CYP1A2 Metabolizing Activity among Lung Cancer Patients and Controls. Basic & Clinical Pharmacology & Toxicology 97, I, 421 (2005).
  • K. Giannioti, A. Papalois, S. Theocharis, N. Drakoulis, P. Galanopoulou: Additive Preventive Effect of Sillybinin and Cimetidine against Paracetamol Induced Hepatotoxicity in Rabbits Basic & Clinical Pharmacology & Toxicology 97, I, 168 (2005).
  • Aikaterini-Christina Tampaki, Thomas Tsaganos, Aikaterini Spyridaki, Basiliki Karagianni, Evangelos J. Giamarellos-Bourboulis, Helen Giamarellou, Diamantis Plachouras and Nikolaos Drakoulis. Alterations of the Expression of CD34 during the Evolution of Sepsis by Ventilator-Associated Pneumonia. Rew. Clin. Pharmacol. Phamacokin. 20: 328-330 (2006).
  • K. Balaskonis, E. Malliara, S. Bauser, S. Markantonis-Kyroudis, A. Papavasiliou, and N. Drakoulis. Genetic Polymorphism of the Metabolic Enzymes CYP1A2, CYP2A6 and NAT-2 in the Greek Population. Impact of NAT-2 Polymorphism in Tuberculosis Treatment. Rew. Clin. Pharmacol. Phamacokin. 20: 75-77 (2006).
  • N. Drakoulis, K. Balaskonis, E. Malliara, E. Livadarou, S. Katsoula. Frequency Distribution of Drug Metabolizing Enzymes CYP2A6 and NAT2 in 390 Healthy Greek Volunteers. Rew. Clin. Pharmacol. Phamacokin. 20: 153-154 (2006).
  • E. Haliassos,, S. Markantonis-Kyroudis, G. Papatheodorou and N. Drakoulis. Assessment of Vancomycin Induced Nephrotoxicity by Determination of Urinary alpha and pi Glutathione S-Transferase. Rew. Clin. Pharmacol. Phamacokin. 20: 168-170 (2006).
  • E. Malliara, K. Balaskonis, E. Haliassos, S. Bauer, K. Kyprianou and N. Drakoulis. Genetic Polymorphism and Lung Cancer Risk: Assessment of the Enzymes’ NAT2 and CYP2A6 Metabolizing Activity in a Case-control Phenotyping Stuby in a Greek Population. Rew. Clin. Pharmacol. Phamacokin. 20: 244-245 (2006).
  • Thomas Tsaganos, Evangelos J Giamarellos-Bourboulis, Spyridon Kollias, Dimitrios Zervakis, Vassiliki Karagianni, Aimilia Pelekanou, Ekaterini-Christina Tampaki, Marina Kontogiorgi, Apostolos Koroneos, Nikolaos Drakoulis, Apostolos Armaganidis, Charis Roussos and Helen Giamarellou. Kinetics of progenitor hemopoetic stem cells in sepsis: Correlation with patients survival? BMC Infectious Diseases, 6: 142-148 (2006).